SecBot SecBot
PRESS-RELEASE ·Filed May 31, 2026

IMCR

Immunocore Holdings plc
BULLISH
Impact 6/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

The Phase 1 data are encouraging but early-stage; the key catalyst is the Phase 3 PRISM-MEL-301 trial readout. Monitor for enrollment updates and interim data. The stock may see modest positive movement on ASCO presentation buzz, but sustained upside depends on Phase 3 results.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$29.13
T+0 close · May 31, 2026 · via day close
Latest settled
+28.39%
T+60 · $37.40
Vs SPY
+27.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $29.13entry
  2. T+1 · 6mo ago +1.48%α +1.33% · $29.56
  3. T+5 · 5mo ago −2.88%α −0.13% · $28.29
  4. T+20 · 5mo ago +8.99%α +10.29% · $31.75
  5. T+60 · 3mo ago +28.39%α +27.16% · $37.40

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immunocore presented updated Phase 1 data for brenetafusp in heavily pretreated advanced melanoma at ASCO 2026, showing a 6-month OS rate of 87% and DCR of 52% in 66 patients. The data support the 160 mcg dose selection for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma. While the results are clinically promising, the small sample size and early-stage nature limit immediate stock-moving impact.

Key Facts

  • Brenetafusp monotherapy in 66 heavily pretreated advanced melanoma patients showed 6-month OS rate of 87% and median OS of 14.3 months.
  • Disease control rate (DCR) was 52% and overall response rate (ORR) was 12%.
  • Data support 160 mcg dose selection for Phase 3 PRISM-MEL-301 trial (brenetafusp + nivolumab vs. standard nivolumab regimens) in first-line advanced melanoma.
  • Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance (median OS 14.7 months).
  • Brenetafusp was generally well tolerated; most common TRAEs were CRS (56%), rash (44%), pyrexia (44%), and chills (38%), predominantly low grade.
  • A second poster showed IL7 may enhance ImmTAC anti-tumor activity in vitro and in vivo.

Financial Impact

No financial data provided; early-stage clinical data with no revenue or guidance impact.

Risk Factors

  • Phase 3 trial may fail to replicate Phase 1 efficacy in a larger, randomized setting.
  • Competition from existing PD-1/CTLA-4 and LAG-3 therapies in first-line melanoma.
  • Safety profile includes CRS and lymphopenia, which could limit tolerability in broader patient populations.
  • Small sample size (n=66) limits statistical reliability of efficacy estimates.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
78% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303917

Track record

14 reports on IMCR

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $32.38 Now $28.88 −10.81% settles Feb 8
  2. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $30.99 Now $28.88 −6.81% settles Feb 4
  3. Nov 6, 202610d ago 8-K Neutral 4/10 No price data
  4. Nov 6, 202610d ago Press Release Bearish 5/10 Entry $30.99 Now $28.88 +6.81% settles Feb 4
  5. Oct 29, 202618d ago Press Release Neutral 3/10 Entry $31.27 Now $28.88 −7.64% settles Jan 27
  6. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $29.48 Now $28.88 −2.04% settles Jan 12
  7. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $29.41 Now $28.88 −1.80% settles Jan 4
  8. Sep 14, 20269w ago 8-K Bullish 6/10 Entry $32.46 Now $28.88 −11.03% settles Dec 8
  9. Aug 6, 202614w ago 8-K Mixed 5/10 Entry $34.50 to $30.49 Now $28.88 −16.29% ▼ −11.62% −9.95% vs SPY
  10. May 31, 202624w ago Press Release Bullish 6/10 Viewing Entry $29.13 to $37.40 Now $28.88 −0.86% ▲ +28.39% +27.16% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (10h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 31, 2026